Publications by authors named "Jennifer Louth"

Claim this Profile
U
Understanding the immunity gap for serogroup B invasive meningococcal disease due to non-pharmaceutical interventions during the Covid-19 pandemic.
Jennifer Louth, Ann Holland, Chloe Chum, Luke Morgan, Simon Tonge

Vaccine· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1/2a clinical trial to assess safety and immunogenicity of an adenoviral-vectored capsular group B meningococcal vaccine.
Christina Dold, Blanché Oguti, Laura Silva-Reyes, Anna Stanzelova, Meriel Raymond, Jennifer Louth

Sci Transl Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanoparticles displaying fHbp elicit an enhanced antibody response against meningococcal B isolates compared to low valency fHbp antigens.
Julia L McKechnie, Elizabeth Kepl, Jennifer Louth, Christina J Sun, Jay Lucidarme

Vaccine· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label, phase IV randomised controlled trial of two schedules of a four-component meningococcal B vaccine in UK preterm infants.
Anna Calvert, Nick Andrews, Sheula Barlow, Ray Borrow, Charlotte Black, Jennifer Louth

Arch Dis Child· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Propositive follow-up: Long-term immune responses to the 4CMenB and MenACWY vaccines in people living with HIV.
Alberto San Francisco Ramos, Catherine Isitt, Shehnaz Athaide, Shamez N Ladhani, Nicholas J Andrews, Jennifer Louth

HIV Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation and use of a serum bactericidal antibody assay for Neisseria meningitidis serogroup X in a seroprevalence study in Niger, West Africa.
Sara Katz, Kelly Townsend-Payne, Jennifer Louth, Lisa Lee-Jones, Caroline Trotter

Vaccine· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Invasive serogroup B meningococci in England following three years of 4CMenB vaccination - First real-world data.
Jay Lucidarme, Xilian Bai, Aiswarya Lekshmi, Stephen A Clark, Laura Willerton, Jennifer Louth

J Infect· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amyloid binding and beyond: a new approach for Alzheimer's disease drug discovery targeting Aβo-PrP binding and downstream pathways.
James D Grayson, Matthew P Baumgartner, Cleide Dos Santos Souza, Samuel J Dawes, Imane Ghafir El Idrissi, Jennifer C Louth

Chem Sci· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meningococcal Serogroup A, B, C, W, X, and Y Serum Bactericidal Antibody Assays.
Jay Lucidarme, Jennifer Louth, Kelly Townsend-Payne, Ray Borrow

Methods Mol Biol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect on meningococcal serogroup W immunogenicity when Tdap was administered prior, concurrent or subsequent to the quadrivalent (ACWY) meningococcal CRM-conjugate vaccine in adult Hajj pilgrims: A randomised controlled trial.
Mohamed Tashani, Al-Mamoon Badahdah, Mohammad Alfelali, Osamah Barasheed, Amani S Alqahtani, Jennifer Louth

Vaccine· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prion chemical biology: on the road to therapeutics?
Beining Chen, Mark Thompson, Jennifer Louth, Kai Guo

Curr Top Med Chem· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and evaluation of 1-amino-6-halo-β-carbolines as antimalarial and antiprion agents.
Mark J Thompson, Jennifer C Louth, Susan M Little, Matthew P Jackson, Yohan Boursereau

ChemMedChem· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 6-substituted indole-3-glyoxylamides as lead antiprion agents with enhanced cell line activity, improved microsomal stability and low toxicity.
Mark J Thompson, Jennifer C Louth, Steven Ferrara, Matthew P Jackson, Fiona J Sorrell

Eur J Med Chem· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2,4-diarylthiazole antiprion compounds as a novel structural class of antimalarial leads.
Mark J Thompson, Jennifer C Louth, Susan M Little, Beining Chen, Iain Coldham

Bioorg Med Chem Lett· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationship refinement and further assessment of indole-3-glyoxylamides as a lead series against prion disease.
Mark J Thompson, Jennifer C Louth, Steven Ferrara, Fiona J Sorrell, Benjamin J Irving

ChemMedChem· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved 2,4-diarylthiazole-based antiprion agents: switching the sense of the amide group at C5 leads to an increase in potency.
Mark J Thompson, Jennifer C Louth, Gemma K Greenwood, Fiona J Sorrell, Sandra G Knight

ChemMedChem· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and structure-activity relationship of indole-3-glyoxylamide libraries possessing highly potent activity in a cell line model of prion disease.
Mark J Thompson, Vinciane Borsenberger, Jennifer C Louth, Katie E Judd, Beining Chen

J Med Chem· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis